239 related articles for article (PubMed ID: 31097097)
1. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
Galli G; Triulzi T; Proto C; Signorelli D; Imbimbo M; Poggi M; Fucà G; Ganzinelli M; Vitali M; Palmieri D; Tessari A; de Braud F; Garassino MC; Colombo MP; Lo Russo G
Lung Cancer; 2019 Jun; 132():72-78. PubMed ID: 31097097
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
Galli G; De Toma A; Pagani F; Randon G; Trevisan B; Prelaj A; Ferrara R; Proto C; Signorelli D; Ganzinelli M; Zilembo N; de Braud F; Garassino MC; Lo Russo G
Lung Cancer; 2019 Nov; 137():38-42. PubMed ID: 31526910
[TBL] [Abstract][Full Text] [Related]
3. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
Maymani H; Hess K; Groisberg R; Hong DS; Naing A; Piha-Paul S; Janku F; Fu S; Tsimberidou AM; Pant S; Karp D; Liu S; Sun M; Heymach J; Simon G; Meric-Bernstam F; Subbiah V
Lung Cancer; 2018 Jun; 120():137-141. PubMed ID: 29748008
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy.
Hamada K; Yoshimura K; Hirasawa Y; Hosonuma M; Murayama M; Narikawa Y; Ariizumi H; Ohkuma R; Shida M; Kubota Y; Matsukuma S; Ishiguro T; Sambe T; Horiike A; Kuramasu A; Wada S; Tsurutani J; Inoue E; Uchida N; Kiuchi Y; Kobayashi S; Hoffman RM; Tsunoda T
Anticancer Res; 2021 Oct; 41(10):4985-4993. PubMed ID: 34593446
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implication of erector spinae muscles in non-small-cell lung cancer patients treated with immuno-oncology combinatorial chemotherapy.
Araki T; Kitaguchi Y; Suzuki Y; Komatsu M; Sonehara K; Wada Y; Tateishi K; Hanaoka M
Thorac Cancer; 2021 Nov; 12(21):2857-2864. PubMed ID: 34599854
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
7. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis.
Lurienne L; Cervesi J; Duhalde L; de Gunzburg J; Andremont A; Zalcman G; Buffet R; Bandinelli PA
J Thorac Oncol; 2020 Jul; 15(7):1147-1159. PubMed ID: 32173463
[TBL] [Abstract][Full Text] [Related]
8. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
Dudnik E; Bshara E; Grubstein A; Fridel L; Shochat T; Roisman LC; Ilouze M; Rozenblum AB; Geva S; Zer A; Rotem O; Allen AM; Peled N
Lung Cancer; 2018 Oct; 124():117-124. PubMed ID: 30268448
[TBL] [Abstract][Full Text] [Related]
9. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types.
Kulkarni AA; Ebadi M; Zhang S; Meybodi MA; Ali AM; DeFor T; Shanley R; Weisdorf D; Ryan C; Vasu S; Rashidi A; Patel MR
ESMO Open; 2020 Sep; 5(5):e000803. PubMed ID: 32900789
[TBL] [Abstract][Full Text] [Related]
11. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
Fucà G; Galli G; Poggi M; Lo Russo G; Proto C; Imbimbo M; Vitali M; Ganzinelli M; Lanti C; Molino G; Stangoni F; Zilembo N; de Braud F; Garassino MC; Signorelli D
Target Oncol; 2018 Dec; 13(6):795-800. PubMed ID: 30306460
[TBL] [Abstract][Full Text] [Related]
12. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
[TBL] [Abstract][Full Text] [Related]
13. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S
Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
[TBL] [Abstract][Full Text] [Related]
14. Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Galli G; Corsetto PA; Proto C; Lo Russo G; Ganzinelli M; Rulli E; Legramandi L; Morelli D; Ferrara R; Prelaj A; Signorelli D; De Toma A; Brambilla M; Occhipinti M; Manglaviti S; Boeri M; Martinetti A; Vingiani A; Colombo MP; Rizzo AM; Torri V; de Braud F; Sangaletti S; Sica A; Garassino MC
Clin Lung Cancer; 2022 Nov; 23(7):e489-e499. PubMed ID: 35948460
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic Use Does Not Appear to Influence Response to Nivolumab.
Kaderbhai C; Richard C; Fumet JD; Aarnink A; Foucher P; Coudert B; Favier L; Lagrange A; Limagne E; Boidot R; Ghiringhelli F
Anticancer Res; 2017 Jun; 37(6):3195-3200. PubMed ID: 28551664
[TBL] [Abstract][Full Text] [Related]
16. Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
Pérol M; Winfree KB; Cuyun Carter G; Lin Cui Z; Bowman L; Garon EB
Lung Cancer; 2019 May; 131():6-13. PubMed ID: 31027699
[TBL] [Abstract][Full Text] [Related]
17. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
18. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
[TBL] [Abstract][Full Text] [Related]
19. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
[TBL] [Abstract][Full Text] [Related]
20. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
